NewsfeedFollowed Companies

Akcea Therapeutics's Competitors, Revenue, Number of Employees, Funding and Acquisitions

Akcea Therapeutics develops and commercializes RNA-targeted antisense therapeutics for the treatment of cardiometabolic ... Read more

Based on data from Akcea Therapeutics's latest SEC filings

Annual Revenue

Based on data from Akcea Therapeutics's latest SEC filings

Employees

Damien McDevitt's photo - Interim-CEO of Akcea Therapeutics

Interim-CEO

Damien McDevitt

CEO Approval Rating

90/100

OVERVIEW

Founded:

2015

Headquarters:

BostonMassachusetts

Status:

PublicIndependent Company of NASDAQAKCA

Industry Sector:

Biotechnology

Pharmaceuticals

SIC Code:

2836NAICS listing »

2834NAICS listing »

Top Competitors or Alternatives

Missing a competitor? Contribute!

Weigh-in!

Help the Owler community know more

Competitor - 1/1

Is Masters a competitor of Akcea Therapeutics?

I don't know

Trending News for Akcea Therapeutics and Akcea Therapeutics's Competitors

Today 1:02 AM

centralcharts

CORRECTION: BridgeBio and Eidos Present Data from Phase 2 Open Label Extension Suggesting Long-term Tolerability of AG10 and Stabilization of Transthyretin Amyloid Cardiomyopathy Disease Measures

AG10 was Well Tolerated with Median 65 Weeks Follow-up since Phase 2 Initiation Rates of All-Cause Mo... See more »

November 14, 2019

Benzinga

CymaBay Therapeutics to Present at Upcoming Investor Conferences

NEWARK, Calif., Nov. 14, 2019 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a clinica... See more »

November 14, 2019

GlobeNewswire

NGM Bio to Present at the Stifel 2019 Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Nov. 14, 2019 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (Nasdaq: ... See more »

Competitive Analysis

TOP COMPETITORS OR ALTERNATIVES

Alnylam is Akcea Therapeutics's #1 rival. Alnylam was founded in 2002 in Cambridge, Massachusetts. Like Akcea Therapeutics, Alnylam also operates in the Pharmaceuticals space. Alnylam generates $261.2M less revenue than Akcea Therapeutics.

Eidos Therapeutics is one of Akcea Therapeutics's top competitors. Eidos Therapeutics is headquartered in San Francisco, California, and was founded in 2013. Like Akcea Therapeutics, Eidos Therapeutics also works within the Biotechnology sector. Eidos Therapeutics generates 24% the revenue of Akcea Therapeutics.

NGM Bio is seen as one of Akcea Therapeutics's top competitors. NGM Bio was founded in 2008, and its headquarters is in South San Francisco, California. Like Akcea Therapeutics, NGM Bio also works within the Biotechnology sector. NGM Bio has 84 fewer employees than Akcea Therapeutics.

RANK

COMPANY

LEADERSHIP

CEO SCORE

EMPLOYEES

TOTAL FUNDING

REVENUE

Damien McDevitt

Interim-CEO

- -
248
$668.2M
$430.3M
1

John Maraganore

CEO

92/100
1,065
$417.5M
$169.1M
2

Neil Kumar

CEO

86/100
24
$170.3M
$26.7M
3

David J. Woodhouse

CEO

91/100
164
$344.8M
$86.3M
4

Sujal Shah

President & CEO

88/100
21
$86.6M
$5.2M
5

Pascal Prigent

CEO

80/100
170
$521.9M
$8.3M
6

Dennis Smith

CEO

70/100
72
- -
$28M
7

Wendy Shusko

President & CEO

67/100
84
- -
$5M
8

Robert Irene

President

70/100
10
- -
$10M
9

Frederick D. Sancilio

Chairman & CEO

78/100
278
$20M
$7.8M
10

Edwin Moses

Chairman & CEO

63/100
438
$82.8M
$66.6M
The top 10 competitors in Akcea Therapeutics' competitive set are Alnylam, Eidos Therapeutics, NGM Bio, CymaBay, Genfit, Masters, WellSpring, Armada Health Care, Sancilio and Company and Ablynx. Together they have raised over 1.6B between their estimated 2.3K employees. Akcea Therapeutics has 248 employees and is ranked 4th among it's top 10 competitors. The top 10 competitors average 234.

Quarterly and Annual Revenue

Trailing 12-Months Trend (TTM)

Annual Revenue

$430.3M

Akcea Therapeutics's revenue is the ranked 1st among it's top 10 competitors. The top 10 competitors average 76.7M. Over the last four quarters, Akcea Therapeutics's revenue has decreased by 28.6%. Specifically, in Q3 2019's revenue was $20.6M; in Q2 2019, it was $46.4M; in Q1 2019, it was $334.4M; in Q4 2018, Akcea Therapeutics's revenue was $28.9M.

Acquisitions

No recent acquisitions found related to Akcea Therapeutics

Akcea Therapeutics Funding History

Since Akcea Therapeutics was founded in 2015, it has participated in 2 rounds of funding. In total Akcea Therapeutics has raised $668.2M. Akcea Therapeutics' last funding round was on Dec 2015 for a total of $543.2M

ROUND

FUNDING DATE

AMOUNT

INVESTORS

Equity
Dec 2015
$543.2M
-
IPO
Jul 2017
$125M
-

Total Funding: $668.2M

Since Akcea Therapeutics was founded in 2015, it has participated in 2 rounds of funding. In total Akcea Therapeutics has raised $668.2M. Akcea Therapeutics' last funding round was on Dec 2015 for a total of $543.2M

Investments

No recent investments found related to Akcea Therapeutics

Akcea Therapeutics News

October 22, 2019BioSpace

Akcea Therapeutics to Hold Third Quarter 2019 Financial Results WebcastWebcast scheduled for Tuesday, November 5th at 4:30 p.m. Eastern Time

Akcea Therapeutics, Inc., an affiliate of Ionis Pharmaceuticals, Inc., announced that it will host a ... See more »
October 21, 2019Insider Monkey

Hedge Funds Have Never Been This Bullish On Akcea Therapeutics, Inc. (AKCA)

See more »
October 13, 2019Business Medical Dialogues

Pfizer, Akcea enter licensing agreement for investigational antisense therapy AKCEA-ANGPTL3-LRx

New Delhi: Pfizer Inc. and Akcea Therapeutics, Inc., a majority-owned affiliate of Ionis Pharmaceutic... See more »
October 9, 2019Pharmabiz

Akcea, Pfizer ink licensing pact for antisense therapy AKCEA─ANGPTL3─Lrx to treat cardiovascular & metabolic diseases

Akcea Therapeutics, a majority─owned affiliate of Ionis Pharmaceuticals, and Pfizer have entered into... See more »
October 7, 2019BioPharma Dive

Akcea inks deal with Pfizer, rebounding after leadership shuffle

Two weeks after a mass C-suite departure, a $250 million payment from Pfizer shored up Akcea's financ... See more »
October 7, 2019The Pharma Letter

Akcea and Ionis partner with Pfizer on CV and metabolic diseases

Shares of Akcea Therapeutics, a majority-owned affiliate of Ionis Pharmaceuticals, leapt 22.3% to $18... See more »
October 1, 2019Zacks

Akcea Therapeutics Enters Oversold Territory

Akcea Therapeutics, Inc. (AKCA) has been on a bit of a cold streak lately, but there might be light a... See more »

Akcea Therapeutics Press Releases

July 16, 2019GlobeNewswire

hATTR Compass Genetic Testing Program Continues to Expand and Enable Diagnosis and Treatment of Hereditary ATTR Amyloidosis One Year Following Launch

Akcea and Ambry Genetics grow partnership, providing easily accessible, no-cost, confidential genetic... See more »
May 8, 2019GlobeNewswire

Akcea Reports Financial Results and Highlights for First Quarter 2019

Achieved First Quarter 2019 TEGSEDI® (inotersen) Global Net Product Revenues of $7 Million... See more »
May 7, 2019StreetInsider

New Long-Term TEGSEDI Safety and Efficacy Data Featured as an Oral Presentation at 2019 American Academy of Neurology Annual Meeting (AAN)

BOSTON and CARLSBAD, Calif., May 07, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA)... See more »
February 28, 2019GlobeNewswire

Akcea® Recognizes Rare Disease Day Through Efforts to Increase Awareness of Hereditary Transthyretin Amyloidosis and Familial Chylomicronemia Syndrome

Planned activities to highlight wide-ranging impact of rare diseases on patients and challenges in di... See more »
February 13, 2019GlobeNewswire

Akcea Therapeutics to Hold Fourth Quarter and Full Year 2018 Financial Results Webcast

Webcast scheduled for Tuesday, February 26th at 4:30 p.m. Eastern TimeWebcast scheduled for Tuesday, ... See more »
November 29, 2018GlobeNewswire

Akcea Announces Upcoming Data Presentations at the 2018 American Society of Hematology Annual Meeting

Presentations focus on the benefits of treatment with TEGSEDI (inotersen) and results show continued ... See more »
November 2, 2018StreetInsider

Akcea Recognizes First Global Familial Chylomicronemia Syndrome (FCS) Awareness Day

Akcea Therapeutics, Inc. (NASDAQ: AKCA), an affiliate of Ionis Pharmaceuticals, Inc., today recognize... See more »

Akcea Therapeutics Videos

Headquarters

22 Boston Wharf Road 9th Floor

Boston, Massachusetts02210

617-207-0202

Driving Directions »

Trending Companies

Summary

ABOUT

Overview

Akcea Therapeutics develops and commercializes RNA-targeted antisense therapeutics for the treatment of cardiometabolic lipid disorders. Akcea Therapeutics was founded in 2015. Akcea Therapeutics' headquarters is located in Boston, Massachusetts, USA ...

CEO

Akcea Therapeutics's Interim-CEO, Damien McDevitt, currently has an approval rating of 90%. Akcea Therapeutics's primary competitors are Alnylam, Eidos Therapeutics & NGM Bio.

Website

akceatx.com

Frequently Asked Questions about Akcea Therapeutics

  1. When was Akcea Therapeutics founded?

    Akcea Therapeutics was founded in 2015

  2. Who is Akcea Therapeutics's CEO?

    Akcea Therapeutics's CEO is Damien McDevitt

  3. How much revenue does Akcea Therapeutics generate?

    Akcea Therapeutics generates $430.3M in revenue

  4. How much funding does Akcea Therapeutics have?

    Akcea Therapeutics has historically raised $668.2M in funding

  1. Where is Akcea Therapeutics's headquarters?

    Akcea Therapeutics's headquarters is in Boston Massachusetts, USA

  2. How many employees does Akcea Therapeutics have?

    Akcea Therapeutics has 248 employees

  3. What sector does Akcea Therapeutics operate in?

    Akcea Therapeutics is in Biotechnology, Pharmaceuticals

  4. Who are Akcea Therapeutics's competitors?

    Akcea Therapeutics's top competitors are Alnylam, Eidos Therapeutics, NGM Bio
Stay up-to-date with the latest news on Akcea Therapeutics